Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code AGR

16. Specific lobbying issues

Climate Change
---FY 2024 Appropriations
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (Discussion Draft)
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Implementation of the Inflation Reduction Act (IRA) of 2022

Foreign Agricultural Biotechnology Laws and Regulations
---Mexico Draft Decree Banning Genetically Modified Corn

Funding for the USDA
---FY 2024 Appropriations

Genetically Engineered (GE) Animals
---ADUFA
---Farm Bill Reauthorization

Genetically Engineered (GE) Plants
---EPA proposed revisions to regulations related to the oversight of certain plant-incorporated protectants (PIPs)

USDA/APHIS Agricultural Biotechnology Regulations
---H.R.1472/S.802: Plant Biostimulant Act
---Farm Bill Reauthorization

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Agriculture - Dept of (USDA), Environmental Protection Agency (EPA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ANI

16. Specific lobbying issues

Antibiotic Use in Livestock
---H.R.4012: To repeal the guidance titled "CVM GFI #263 Recommendations for Sponsors of Medically Important Antimicrobial Drugs Approved for Use in Animals to Voluntarily Bring Under Veterinary Oversight All Products That Continue to be Available Over-the-Counter".

Genetically Engineered (GE) Animals
---ADUFA

Issues Relating to Non-Human Primate Shortages

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Fish & Wildlife Service (USFWS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

H.R. 2811: Limit, Save, Grow Act of 2023

Funding for Antimicrobial Resistance (AMR) Programs
---FY 2024 Appropriations
---H.R.2940/S.1355: PASTEUR Act
---DISARM Act (Discussion Draft)
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---FY 2024 Appropriations
---Funding for Strategic National Stockpile
---Health Defense Operations Funding Designation
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Reauthorization of PAHPA

Funding for Biofuels, Biomass Crop Assistance, and Biorefineries
---FY 2024 Appropriations

Funding for the Centers for Disease Control and Prevention Vaccine Programs
---FY 2024 Appropriations
---Funding for Routine Immunization Infrastructure during Pandemic
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020

Funding for FDA
---FY 2024 Appropriations
---Implementation of the Prescription Drug User Fee Act (PDUFA) VII Priorities

Funding for Health Resources and Services Administration (HRSA)
---FY 2024 Appropriations
---National Vaccine Injury Compensation Program (VICP)

Funding for the HHS Office of Infectious Disease and HIV/AIDS Policy
---FY 2024 Appropriations

Funding for National Institutes of Health
---FY 2024 Appropriations
---Advanced Research Projects Agency for Health (ARPA-H) Act

Funding for Renewable Chemicals/Bio-based Products
---FY 2024 Appropriations
---Implementation of the Inflation Reduction Act (IRA) of 2022

Pandemic Preparedness
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Implementation of the Prepare for and Respond to Existing Viruses, Emerging New Threats and (PREVENT) Pandemics Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CHM

16. Specific lobbying issues

Funding for Renewable Chemicals/Bio-based Products

Renewable Chemicals/Bio-based Products (Non-Funding)
---Investment Tax Credit

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Antitrust Legislation

Bayh-Dole Act/Tech Transfer
---Bayh-Dole Act
---March-In Rights
---U.S. Senate Committee on Health, Education, Labor, and Pensions (HELP) Discussion Draft on PAHPA Reauthorization

Compulsory Licensing
---Prescription Drug Price Relief Act (Discussion Draft)

Data Privacy Issues
---American Data Privacy and Protection Act (Discussion Draft)

Drug Patenting
---S.79/H.R.1717: Interagency Patent Coordination and Improvement Act of 2023
---S.113: Prescription Pricing for the People Act of 2023
---S.142: Preserve Access to Affordable Generics and Biosimilars Act
---S.148: Stop STALLING Act
---S.150: Affordable Prescriptions for Patients Act of 2023
---S.1128: A bill to establish special rules relating to information provided with respect to drug applications concerning method of use patents
---Restrictions on Intellectual Property Rights

Intellectual Property Enforcement
---TRIPS Waiver

Inter Partes Review
---Patent Eligibility Restoration Act of 2023
---Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (Discussion Draft)
---Restoring Americas Leadership in Innovation Act (Discussion Draft)

Pandemic Preparedness
---H.R.3858/S.1834: A bill to prohibit the President from negotiating or concluding any withdrawal, suspension, waiver, or modification to the Agreement on Trade-Related Aspects of Intellectual Property Rights without explicit authorization from Congress.
---Restrictions on Intellectual Property Rights
---TRIPS Waiver

Patent Reform
---S.79/H.R.1717: Interagency Patent Coordination and Improvement Act of 2023
---Patent Litigation Reform
---Patent Trial and Appeal Board Reform Act (Discussion Draft)

Patenting of Biological Inventions
---PTO Examination Guidelines
---Section 101 Modernization

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Patent & Trademark Office (PTO), U.S. International Trade Commission (ITC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ENG

16. Specific lobbying issues

Biofuels (Non-Funding)
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Incentives for Sustainable Aviation Fuels

Biomass Programs (Non-Funding)

Biorefineries (Non-Funding)

Climate Change

Funding for Biofuels, Biomass Crop Assistance, and Biorefineries
---Incentives for Sustainable Aviation Fuels

Renewable Fuel Standard (RFS)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code FOO

16. Specific lobbying issues

Antibiotic Use in Livestock
--- H.R.4012: To repeal the guidance titled "CVM GFI #263 Recommendations for Sponsors of Medically Important Antimicrobial Drugs Approved for Use in Animals to Voluntarily Bring Under Veterinary Oversight All Products That Continue to be Available Over-the-Counter".

Genetically Engineered (GE) Animals
---ADUFA
---Farm Bill Reauthorization
---Labeling

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code FUE

16. Specific lobbying issues

Biofuels (Non-Funding)
---Incentives for Sustainable Aviation Fuels
---Sustainable Aviation Fuels Tax Credit

Biomass Programs (Non-Funding)

Biorefineries (Non-Funding)

Climate Change

Funding for Biofuels, Biomass Crop Assistance, and Biorefineries
---Incentives for Sustainable Aviation Fuels

Renewable Fuel Standard (RFS)

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

340B Drug Discount Program
---H.R.2534: PROTECT 340B Act of 2023
---340B Accountability Act (Discussion Draft)
---Program Implementation & Oversight
---Senate request for information (RFI) on the 340B Drug Pricing Program

Accelerated Approval
---H.R.2408: Access to Innovative Treatments Act of 2023

Alternative Funding Programs

Biodefense Research, Development and Procurement Issues (Non-Funding)
---H.R.3577: Medical and Health Stockpile Accountability Act of 2023
---H.R.3613: Doctors at the Ready Act
---H.R.3631: State Strategic Stockpile Act of 2023
---H.R.3703: Helping Evaluate Appropriate Logistical Infrastructure for National Government (HEALING) Response Act of 2023
---H.R.3742: To direct the Comptroller General of the United States to evaluate the Federal Governments collection and sharing of public health data to respond to public health emergencies.
---H.R.3791: Improving Data Accessibility Through Advancements (DATA) in Public Health Act
---H.R.3794: Fast-Track Logistics for Acquiring Supplies in a Hurry (FLASH) Act of 2023
---H.R.3795: To amend the Public Health Service Act to require the development of a diagnostic testing preparedness plan to be used during public health emergencies, and for other purposes.
---H.R.3813: CDC Leadership Accountability Act
---H.R.3820: To amend the Public Health Service Act to strike the requirement that the Director of the Centers for Disease Control and Prevention be appointed by and with the advice and consent of the Senate
---H.R.3832: Disease X Act of 2023
---H.R.3837: Improving Public Health Preparedness Act
---H.R.3840: Ensuring Sufficient Supply of Testing Act
---American Pandemic Preparedness Plan (AP3)
---Biosecurity Infrastructure for Operational (BIO) Early Warning Act (Discussion Draft)
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---MCM PRV Program
---PHE Congressional Review Act of 2023 (Discussion Draft)
---PHEMCE Advisory Committee Act of 2023 (Discussion Draft)
---Public Health Guidance Transparency and Accountability Act (Discussion Draft)
---Reauthorization of PAHPA
---Tropical Disease Priority Review Voucher (PRV) Program
---White House National Biodefense Strategy

Climate Change
---FY 2024 Appropriations
---Implementation of the Inflation Reduction Act (IRA) of 2022

Data Privacy
---American Data Privacy and Protection Act (Discussion Draft)

Diagnostics and Personalized Medicine Regulation and Oversight

Diversity & Inclusion
---Implementation of the Prepare for and Respond to Existing Viruses, Emerging New Threats and (PREVENT) Pandemics Act
---Decentralized Clinical Trials

Drug Evaluation and Review
---COVID-19 Lessons Learned
---FDA Hiring Flexibility
---FDA Management and Financial Accountability

Drug Importation

Drug Manufacturing, Quality & Distribution
---Advanced Manufacturing
---Counterfeiting
---Drug Shortages
---Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
---Executive Order on Buy American
---Pharmacy Compounding & Oversight
---Supply Chain Integrity and Traceability

Drug Patenting
---S.79/H.R.1717: Interagency Patent Coordination and Improvement Act of 2023
---S.113: Prescription Pricing for the People Act of 2023
---S.142: Preserve Access to Affordable Generics and Biosimilars Act
---S.148: Stop STALLING Act
---S.150: Affordable Prescriptions for Patients Act of 2023
---S.1128: A bill to establish special rules relating to information provided with respect to drug applications concerning method of use patents.
---Restrictions on Intellectual Property Rights

Drug Pricing
---FY 2024 Appropriations
---H.R.2408: Access to Innovative Treatments Act
---S.79/H.R.1717: Interagency Patent Coordination and Improvement Act of 2023
---S.113: Prescription Pricing for the People Act of 2023
---S.127: Pharmacy Benefit Manager Transparency Act of 2023
---S.142: Preserve Access to Affordable Generics and Biosimilars Act
---S.150: Affordable Prescriptions for Patients Act of 2023
---S.476: Maintaining Investments in New Innovation Act
---S.1128: A bill to establish special rules relating to information provided with respect to drug applications concerning method of use patents
---S.1246: SMART Prices Act
---COVID-19 Pricing-Related Provisions
---Expanding small business exemption in the Inflation Reduction Act (IRA) of 2022
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Medicare Reimbursement Policies
---National Coverage Determination
---Patient Cost-Sharing and Smoothing

Foreign Drug Data Protection Laws

Funding for Antimicrobial Resistance (AMR) Programs
---FY 2024 Appropriations
---H.R.2940/S.1355: PASTEUR Act
---DISARM Act (Discussion Draft)
---National Defense Authorization Act for FY 2024


Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---FY 2024 Appropriations
---Funding for Strategic National Stockpile
---Health Defense Operations Funding Designation
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Reauthorization of PAHPA

Funding for the Centers for Disease Control and Prevention Vaccine Programs
---FY 2024 Appropriations
---H.R.2408: Access to Innovative Treatments Act of 2023
---Funding for 2024-2025 Influenza Season Preparedness and Response
---Funding for Routine Immunization Infrastructure during Pandemic
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020

Funding for FDA
---FY 2024 Appropriations
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (Discussion Draft)
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Prescription Drug User Fee Act (PDUFA) VII Priorities

Funding for Health Resources and Services Administration (HRSA)
---FY 2024 Appropriations

Funding for National Institutes of Health
---FY 2024 Appropriations
---Advanced Research Projects Agency for Health (ARPA-H) Act

Funding for the HHS Office of Infectious Disease and HIV/AIDS Policy
---FY 2024 Appropriations

Generic Drug Entry
---S.148: Stop STALLING Act
---S.775: Increasing Transparency in Generic Drug Applications Act
---Incentives for Generic Entry

Medicaid
---Pricing and Rebates

Opioid Crisis
---SUPPORT Act (Discussion Draft)

Orphan Drug Issues
---Expanding drug exclusion in the Inflation Reduction Act (IRA) of 2022
---Finding Orphan-Disease Remedies with Antifungal Research and Development (FORWARD) Act (Discussion Draft)
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Orphan Drug Tax Credit
---Retaining Access and Restoring Exclusivity (RARE) Act (Discussion Draft)

Pandemic Preparedness
---H.R.3066: Pandemics Require Evaluating, Planning, And Responding Effectively (PREPARE) Act
---Implementation of the Prepare for and Respond to Existing Viruses, Emerging New Threats and (PREVENT) Pandemics Act
---Supply Chain Issues
---Temporarily Refundable R&D Credit
---TRIPS Waiver
---WHO Pandemic Preparedness Accord

Rare Pediatric Disease Priority Review
---Helping Experts Accelerate Rare Treatments (HEART) Act (Discussion Draft)
---Speeding Therapy Access Today (STAT) Act (Discussion Draft)

Reimbursement and Coverage of Innovative Products
---H.R.133: Mandating Exclusive Review of Individual Treatments (MERIT) Act
---H.R.830/S.1375: HELP Copays Act
---H.R.2408: Access to Innovative Treatments Act of 2023
---S.652/H.R.2630 Safe Step Act
---Administration Rebate Rule
---CMMI Authority
---In-Home Administration of Part B Drugs
---Lower Costs, More Cures Act (Discussion Draft)
---Medicare Drug Price Negotiation Act (Discussion Draft)
---National Coverage Determination
---Patient Cost-Sharing and Smoothing
---Prescription Drug Price Relief Act (Discussion Draft)
---Protected Classes
---Seniors Prescription Drug Relief Act (Discussion Draft)
---Support of Patient Premiums and Cost-Sharing Obligations
---Value-based Contracting and Communications
---Value-Based Purchasing (VBP) Rule

Vaccines and Infectious Diseases
---FY 2024 Appropriations
---H.R.133: Mandating Exclusive Review of Individual Treatments (MERIT) Act
---H.R.2408: Access to Innovative Treatments Act of 2023
---H.R.2940/S.1355: PASTEUR Act
---Adult Immunization
---DISARM Act (Discussion Draft)
---Maternal Immunization
---MCM Manufacturing & Capacity
---MCM R&D Incentives
---Monoclonal Antibody Coverage and Utilization
---National Coverage Determination
---Vaccine and Antimicrobial Resistance Product Development and Incentives
---Vaccine and Coverage Certainty (VACC) Act (Discussion Draft)
---Vaccine Injury Compensation Modernization Act (Discussion Draft)
---Vaccine Injury Compensation Program
---Vaccine Quality Measure
---Vaccine Safety

Vaccine Injury Compensation Program
---FY 2024 Appropriations
---Countermeasure Injury Compensation Fund Amendment Act (Discussion Draft)
---Vaccine Access Improvement Act (Discussion Draft)
---Vaccine Injury Compensation Modernization Act (Discussion Draft)
---VICP CICP (Discussion Draft)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), White House Office, Centers For Medicare and Medicaid Services (CMS), State - Dept of (DOS), U.S. Trade Representative (USTR), U.S. International Trade Commission (ITC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HOM

16. Specific lobbying issues

Biodefense Research, Development and Procurement Issues (Non-Funding)
---H.R.3577: Medical and Health Stockpile Accountability Act of 2023
---H.R.3613: Doctors at the Ready Act
---H.R.3631: State Strategic Stockpile Act of 2023
---H.R.3703: Helping Evaluate Appropriate Logistical Infrastructure for National Government (HEALING) Response Act of 2023
---H.R.3742: To direct the Comptroller General of the United States to evaluate the Federal Governments collection and sharing of public health data to respond to public health emergencies.
---H.R.3791: Improving Data Accessibility Through Advancements (DATA) in Public Health Act
---H.R.3794: Fast-Track Logistics for Acquiring Supplies in a Hurry (FLASH) Act of 2023
---H.R.3795: To amend the Public Health Service Act to require the development of a diagnostic testing preparedness plan to be used during public health emergencies, and for other purposes.
---H.R.3813: CDC Leadership Accountability Act
---H.R.3820: To amend the Public Health Service Act to strike the requirement that the Director of the Centers for Disease Control and Prevention be appointed by and with the advice and consent of the Senate.
---H.R.3832: Disease X Act of 2023
---H.R.3837: Improving Public Health Preparedness Act
---H.R.3840: Ensuring Sufficient Supply of Testing Act
---American Pandemic Preparedness Plan (AP3)
---Biosecurity Infrastructure for Operational (BIO) Early Warning Act (Discussion Draft)
---Gene Editing
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Improving Contract Transparency for the SNS Act (Discussion Draft)
---Improving Contract Transparency at BARDA Act (Discussion Draft)
---MCM PRV Program
---PHE Congressional Review Act of 2023 (Discussion Draft)
---PHEMCE Advisory Committee Act of 2023 (Discussion Draft)
---Public Health Guidance Transparency and Accountability Act (Discussion Draft)
---Pandemic Preparedness Plan
---Reasonable Pricing
---Reauthorization of PAHPA
---Tropical Disease Priority Review Voucher (PRV) Program
---White House National Biodefense Strategy
---WHO Pandemic Preparedness Accord Zero Draft

Funding for Antimicrobial Resistance (AMR) Programs
---FY 2024 Appropriations
---H.R.2940/S.1355: PASTEUR Act
---DISARM Act (Discussion Draft)

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---FY 2024 Appropriations
---Funding for Strategic National Stockpile
---Health Defense Operations Funding Designation
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Reauthorization of PAHPA

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MED

16. Specific lobbying issues

Biodefense Research, Development and Procurement Issues (Non-Funding)
---H.R.3577: Medical and Health Stockpile Accountability Act of 2023
---H.R.3613: Doctors at the Ready Act
---H.R.3631: State Strategic Stockpile Act of 2023
---H.R.3703: Helping Evaluate Appropriate Logistical Infrastructure for National Government (HEALING) Response Act of 2023
---H.R.3742: To direct the Comptroller General of the United States to evaluate the Federal Government's collection and sharing of public health data to respond to public health emergencies.
---H.R.3791: Improving Data Accessibility Through Advancements (DATA) in Public Health Act
---H.R.3794: Fast-Track Logistics for Acquiring Supplies in a Hurry (FLASH) Act of 2023
---H.R.3795: To amend the Public Health Service Act to require the development of a diagnostic testing preparedness plan to be used during public health emergencies, and for other purposes.
---H.R.3813: CDC Leadership Accountability Act
---H.R.3820: To amend the Public Health Service Act to strike the requirement that the Director of the Centers for Disease Control and Prevention be appointed by and with the advice and consent of the Senate.
---H.R.3832: Disease X Act of 2023
---H.R.3837: Improving Public Health Preparedness Act
---H.R.3840: Ensuring Sufficient Supply of Testing Act
---American Pandemic Preparedness Plan (AP3)
---Biosecurity Infrastructure for Operational (BIO) Early Warning Act (Discussion Draft)
---Executive Order on Modernizing Influenza Vaccines
---Gene Editing
---Implementation of 21st Century Cures Act of 2016
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of Medical Countermeasure Innovation Act of 2016
---Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act of 2019
---Improving Contract Transparency for the SNS Act (Discussion Draft)
---Improving Contract Transparency at BARDA Act (Discussion Draft)
---MCM PRV Program
---PHE Congressional Review Act of 2023 (Discussion Draft)
---PHEMCE Advisory Committee Act of 2023 (Discussion Draft)
---Public Health Guidance Transparency and Accountability Act (Discussion Draft)
---Reasonable Pricing
---Reauthorization of PAHPA
---Tropical Disease Priority Review Voucher (PRV) Program
---White House National Biodefense Strategy

Funding for Antimicrobial Resistance (AMR) Programs
---FY 2024 Appropriations
---H.R.2940/S.1355: PASTEUR Act
---DISARM Act (Discussion Draft)
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---National Defense Authorization Act for FY 2024

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---FY 2024 Appropriations
---Funding for Strategic National Stockpile
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Reauthorization of PAHPA

Funding for the Centers for Disease Control and Prevention Vaccine Programs
---FY 2024 Appropriations
---Funding for 2024-2025 Influenza Season Preparedness and Response
---Funding for Routine Immunization Infrastructure during Pandemic

Funding for National Institutes of Health
---FY 2024 Appropriations
---Advanced Research Projects Agency for Health (ARPA-H) Act

Pandemic Preparedness
---FY 2024 Appropriations
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---R&D Funding for Medical Countermeasures
---Temporarily Refundable R&D Credit

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

340B Drug Discount Program
---Executive Order on Access to Affordable Life-Saving Medications
---Program Implementation & Oversight
---Senate request for information (RFI) on the 340B Drug Pricing Program

Pandemic Preparedness
---COVID-19 Pricing-Related Provisions
---In-Home Administration of Part B Drugs
---Seniors Prescription Drug Relief Act (Discussion Draft)

Data Privacy
---American Data Privacy and Protection Act (Discussion Draft)

Drug Pricing
---H.R.133: Mandating Exclusive Review of Individual Treatments (MERIT) Act
---H.R.1790: Biologics Competition Act of 2023
---H.R.2408: Access to Innovative Treatments Act of 2023
---S.79/H.R.1717: Interagency Patent Coordination and Improvement Act of 2023
---S.113: Prescription Pricing for the People Act of 2023
---S.127: Pharmacy Benefit Manager Transparency Act of 2023
---S.142: Preserve Access to Affordable Generics and Biosimilars Act
---S.150: Affordable Prescriptions for Patients Act of 2023
---S.1067: Ensuring Timely Access to Generics
---CMMI Authority
---COVID-19 Pricing-Related Provisions
---Expanding small business exemption in the Inflation Reduction Act (IRA) of 2022
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Medicare Drug Price Negotiation Act (Discussion Draft)
---Medicare Negotiation and Competitive Licensing Act (Discussion Draft)
---National Coverage Determination
---Prescription Drug Price Relief Act (Discussion Draft)

Medicaid
---S.127: Pharmacy Benefit Manager Transparency Act of 2023
---Alternative Payment Arrangements for Gene Therapies
---Average Manufacturer Price Calculations
---Coverage of Accelerated Approval Products
---Drug Benefit Design
---Encouraging Innovation Benefit Design to Lower Costs for Seniors Act (Discussion Draft)
---Medicaid VBPs for Patients (MVP) Act
---Pricing and Rebates
---Value-Based Purchasing (VBP) Rule

Reimbursement and Coverage of Innovative Products
---H.R.133: Mandating Exclusive Review of Individual Treatments (MERIT) Act
---H.R.830/S.1375: HELP Copays Act
---H.R.2408: Access to Innovative Treatments Act of 2023
---S.476: Maintaining Investments in New Innovation Act
---S.652/H.R.2630: Safe Step Act
---Administration Rebate Rule
---CMMI Authority
---Expanding drug exclusion in the Inflation Reduction Act (IRA) of 2022
---Implementation of the Inflation Reduction Act (IRA) of 2022
---In-Home Administration of Part B Drugs
---Lower Costs, More Cures Act (Discussion Draft)
---Medicare Part B Physician-Administered Products
---Medicare Prescription Drug Price Negotiation Act (Discussion Draft)
---National Coverage Determination
---New Opportunities for Value that Extend Lives (NOVEL) Act (Discussion Draft)
---Patient Cost-Sharing and Smoothing
---Protected Classes
---Support of Patient Premiums and Cost-Sharing Obligations
---Value-based Contracting and Communications
---Value-Based Purchasing (VBP) Rule

Vaccines and Infectious Diseases
---FY 2024 Appropriations
---H.R.133: Mandating Exclusive Review of Individual Treatments (MERIT) Act
---H.R.2408: Access to Innovative Treatments Act of 2023
---DISARM Act (Discussion Draft)
---National Coverage Determination
---Vaccine Injury Compensation Program
---Value of vaccines and vaccine confidence
---Vaccine safety net and vaccine infrastructure

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code SMB

16. Specific lobbying issues

Banking Policy Impacting Emerging Companies

Capital Formation Incentives
---H.R.368: American Innovation Act of 2023
---H.R.448: Putting Investors First Act of 2023
---H.R.835: Fair Investment Opportunities for Professional Experts Act
---H.R.1579: Accredited Investor Definition Review Act
---H.R.2608: To amend the Federal securities laws to specify the periods for which financial statements are required to be provided by an emerging growth company, and for other purposes.
---H.R.2610: To amend the Securities Exchange Act of 1934 to specify certain registration statement contents for emerging growth companies, to permit issuers to file draft registration statements with the Securities and Exchange Commission for confidential review, and for other purposes.
---H.R.2624: Helping Startups Continue to Grow Act
---H.R.2792: Small Entity Update Act
---H.R.2797: Equal Opportunity for All Investors Act of 2023
---H.R.2799: Expanding Access to Capital Act of 2023
---S.866: American Innovation and Jobs Act
---A bill to amend the Internal Revenue Code of 1986 to add a new medical research component to the credit for increasing research activities (Discussion Draft)
---A bill to amend the Internal Revenue Code of 1986 to make a portion of research credit refundable for certain small businesses engaging in specified medical research. (Discussion Draft)
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Infectious Disease Therapies Research and Innovation Act (Discussion Draft)
---Innovation and Growth Now by Investing in Tomorrow's Enterprises (IGNITE) American Innovation Act (Discussion Draft)
---JOBS Act 4.0
---Net Operating Loss Advance Refunds

Capital Market Enhancements
---Accredited Investor Definition
---JOBS Act 4.0
---SEC Small Business Forum

Mergers and Acquisitions

Pandemic Preparedness
---Temporarily Refundable R&D Credit

Proxy Advisory Services
---Impact of Policies on Small Public Companies

Sarbanes Oxley Section 404 (b)
---Small Issuer Exemption

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

H.R.2811: Limit, Save, Grow Act of 2023

Biofuels (Non-Funding)
---Incentives for Sustainable Aviation Fuels
---Sustainable Aviation Fuels Tax Credit

Capital Formation Incentives
---H.R.368: American Innovation Act of 2023
---H.R.2624: Helping Startups Continue to Grow Act
---H.R.2673: American Innovation and R&D Competitiveness Act
---H.R.2792: Small Entity Update Act
---S.866: American Innovation and Jobs Act
---A bill to amend the Internal Revenue Code of 1986 to add a new medical research component to the credit for increasing research activities (Discussion Draft)
---A bill to amend the Internal Revenue Code of 1986 to make a portion of research credit refundable for certain small businesses engaging in specified medical research. (Discussion Draft)
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Innovation and Growth Now by Investing in Tomorrow's Enterprises (IGNITE) American Innovation Act (Discussion Draft)
---JOBS Act 4.0
---Net Operating Loss Advance Refunds

Orphan Drug Issues
---H.R.1350: Cameron's Law

Renewable Chemicals/Bio-based Products (Non-Funding)
---Investment Tax Credit
---Production Tax Credit

Research & Development Tax Credit Reforms
---H.R.2673: American Innovation and R&D Competitiveness Act
---S.866: American Innovation and Jobs Act
---A bill to amend the Internal Revenue Code of 1986 to provide for credits against tax for domestic medical and drug manufacturing and advanced medical manufacturing equipment. (Discussion Draft)
---Expensing of R&D Expenditures
---House - Section 174 Amortization
---R&D Payroll Credit

Vaccine Injury Compensation Program
---FY 2024 Appropriations
---Countermeasure Injury Compensation Fund Amendment Act (Discussion Draft)
---Vaccine Injury Compensation Modernization Act (Discussion Draft)
---Vaccine Access Improvement Act (Discussion Draft)
---VICP CICP (Discussion Draft)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

Drug Importation

Drug Pricing
---Reference Pricing in Drug Reimbursement

Foreign Agricultural Biotechnology Laws and Regulations
---Mexico Draft Decree Banning Genetically Modified Corn

Intellectual Property International Enforcement
---TRIPS Waiver

Issues Relating to Non-Human Primate Shortages

United Nations

World Health Organization (WHO)
---TRIPS Waiver
---WHO Pandemic Preparedness Accord

World Trade Organization (WTO)
---TRIPS Waiver

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), U.S. International Trade Commission (ITC), State - Dept of (DOS), Agriculture - Dept of (USDA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
No Yes